Critical
Everolimus × Itraconazole
mTOR kinase inhibitor – immunosuppressant and antineoplastic×Antifungal, triazole
Mechanism
Strong CYP3A4 inhibitor – everolimus rises 9-fold. EMA Certican Section 4.3 strict contraindication.
Symptoms
Acute immunosuppression, pneumonitis.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Sources
- EMA: Certican (everolimus) SmPC (2024)– EMA EPAR Certican